Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Accounts Payables: 2019-2024

Historic Accounts Payables for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $8.5 million.

  • Avidity Biosciences' Accounts Payables fell 80.60% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 80.60%. This contributed to the annual value of $8.5 million for FY2024, which is 75.36% down from last year.
  • As of FY2024, Avidity Biosciences' Accounts Payables stood at $8.5 million, which was down 75.36% from $34.3 million recorded in FY2023.
  • Avidity Biosciences' 5-year Accounts Payables high stood at $34.3 million for FY2023, and its period low was $7.7 million during FY2020.
  • For the 3-year period, Avidity Biosciences' Accounts Payables averaged around $25.1 million, with its median value being $32.6 million (2022).
  • As far as peak fluctuations go, Avidity Biosciences' Accounts Payables skyrocketed by 235.57% in 2020, and later slumped by 75.36% in 2024.
  • Yearly analysis of 5 years shows Avidity Biosciences' Accounts Payables stood at $7.7 million in 2020, then skyrocketed by 81.86% to $14.1 million in 2021, then soared by 131.25% to $32.6 million in 2022, then climbed by 5.43% to $34.3 million in 2023, then crashed by 75.36% to $8.5 million in 2024.